Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial

Data from the phase 2 ELM-2 trial recently demonstrated that the CD20×CD3 bispecific antibody odronextamab in patients with relapsed/refractory DLBCL after ≥2 lines of therapy has encouraging efficacy and generally manageable safety. At the 29.9-month efficacy follow-up, the objective response rate was 52.0% and complete response rate was 31.5%. Cytokine release syndrome was the most common treatment-emergent adverse event (53.3% [grade ≥3, 1.7%]).